Cargando…

Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials

The Continual Reassessment Method (CRM) was developed for Phase I trials to identify a maximum‐tolerated dose of an agent using a design in which each participant is treated with a single administration of the agent. We propose an extension of the CRM in which participants receive multiple administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Thomas M., Mercier, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546169/
https://www.ncbi.nlm.nih.gov/pubmed/35662077
http://dx.doi.org/10.1002/sim.9487
_version_ 1784804982529196032
author Braun, Thomas M.
Mercier, Francois
author_facet Braun, Thomas M.
Mercier, Francois
author_sort Braun, Thomas M.
collection PubMed
description The Continual Reassessment Method (CRM) was developed for Phase I trials to identify a maximum‐tolerated dose of an agent using a design in which each participant is treated with a single administration of the agent. We propose an extension of the CRM in which participants receive multiple administrations of an agent using a so‐called step‐up dosing procedure in which participants receive one or more administrations of lower doses of the agent before they receive their penultimate dose. We use methods developed for the CRM to model the probability of DLT for each administration, which leads to the use of conditional probability models to model the joint probability of DLT across multiple administrations. We compare our approach to two existing methods that use time‐to‐event modeling methods for modeling the probability of DLT. We demonstrate through simulations that our approach has operating characteristics similar to existing methods, but due to its foundations in the CRM, ours is simpler to implement than existing approaches and is therefore more likely to be adopted in practice.
format Online
Article
Text
id pubmed-9546169
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95461692022-10-14 Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials Braun, Thomas M. Mercier, Francois Stat Med Research Articles The Continual Reassessment Method (CRM) was developed for Phase I trials to identify a maximum‐tolerated dose of an agent using a design in which each participant is treated with a single administration of the agent. We propose an extension of the CRM in which participants receive multiple administrations of an agent using a so‐called step‐up dosing procedure in which participants receive one or more administrations of lower doses of the agent before they receive their penultimate dose. We use methods developed for the CRM to model the probability of DLT for each administration, which leads to the use of conditional probability models to model the joint probability of DLT across multiple administrations. We compare our approach to two existing methods that use time‐to‐event modeling methods for modeling the probability of DLT. We demonstrate through simulations that our approach has operating characteristics similar to existing methods, but due to its foundations in the CRM, ours is simpler to implement than existing approaches and is therefore more likely to be adopted in practice. John Wiley and Sons Inc. 2022-06-05 2022-09-10 /pmc/articles/PMC9546169/ /pubmed/35662077 http://dx.doi.org/10.1002/sim.9487 Text en © 2022 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Braun, Thomas M.
Mercier, Francois
Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
title Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
title_full Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
title_fullStr Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
title_full_unstemmed Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
title_short Extending the Continual Reassessment Method to accommodate step‐up dosing in Phase I trials
title_sort extending the continual reassessment method to accommodate step‐up dosing in phase i trials
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546169/
https://www.ncbi.nlm.nih.gov/pubmed/35662077
http://dx.doi.org/10.1002/sim.9487
work_keys_str_mv AT braunthomasm extendingthecontinualreassessmentmethodtoaccommodatestepupdosinginphaseitrials
AT mercierfrancois extendingthecontinualreassessmentmethodtoaccommodatestepupdosinginphaseitrials